Literature DB >> 23242569

Survivin expression in medulloblastoma: a possible marker for survival.

Azza Abdel-Aziz1, Mie Ali Ali Mohamed, Fatma Mohamed Farouk Akl, Ahmed Nageeb M Taha.   

Abstract

UNLABELLED: Medulloblastomas are highly invasive tumors which are generally disseminated at the time of diagnosis. High and continued morbidity and mortality have prompted the search for new biologic markers that might be used for targeted therapy to minimise treatment related side effects. In this work, we studied the positive expression of survivin in medulloblastoma and investigated its relation to clinical, pathologic data and survival. Tumor tissue specimens from 47 patients with medulloblastoma who underwent primary surgical treatment from June 2002 to June 2006 at the Mansoura university hospital, Egypt were collected. Paraffin sections of all samples were submitted for immunohistochemistry using anti-survivin antibody. The relation between the percentage of positive survivin cells with clinical, pathological and survival data was evaluated.
RESULTS: In 47 cancer tissue specimens, one case large-cell-anaplastic (1.12 %), tweleve cases desmoplastic (25.53 %) and 34 cases classic medulloblastomas (72.34 %). The immunohistochemical expression of survivin was nulear with moderate intensity. It does not correlate with either age or sex. There was a significant negative correlation of survivin expression with survival (p < 0.001), where negative survivin immunostaining was associated with prolonged overall and disease free survival, while survivin expression was associated with shortened survival.
CONCLUSION: Survivin expression correlate with the clinical outcome with poor prognosis and could be a potential predictive factor for recurrence or metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242569     DOI: 10.1007/s12253-012-9594-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  20 in total

Review 1.  Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors.

Authors:  Rebecca Liu; Duane A Mitchell
Journal:  Cancer Immunol Immunother       Date:  2009-09-16       Impact factor: 6.968

Review 2.  IAP family proteins--suppressors of apoptosis.

Authors:  Q L Deveraux; J C Reed
Journal:  Genes Dev       Date:  1999-02-01       Impact factor: 11.361

Review 3.  Medulloblastoma: clinical and biologic aspects.

Authors:  R J Packer; P Cogen; G Vezina; L B Rorke
Journal:  Neuro Oncol       Date:  1999-07       Impact factor: 12.300

4.  Medulloblastoma: a population-based study of 532 cases.

Authors:  R O Roberts; C F Lynch; M P Jones; M N Hart
Journal:  J Neuropathol Exp Neurol       Date:  1991-03       Impact factor: 3.685

5.  Epidemiology of adult medulloblastoma.

Authors:  M T Giordana; P Schiffer; M Lanotte; P Girardi; A Chio
Journal:  Int J Cancer       Date:  1999-03-01       Impact factor: 7.396

6.  Differential expression of survivin splice isoforms in medulloblastomas.

Authors:  X-N Li; Q Shu; J M Su; A M Adesina; K K Wong; L Perlaky; B A Antalffy; S M Blaney; C C Lau
Journal:  Neuropathol Appl Neurobiol       Date:  2007-02       Impact factor: 8.090

7.  Survivin expression in childhood medulloblastomas: a possible diagnostic and prognostic marker.

Authors:  Bela Bodey; Vivian Bodey; Stuart E Siegel; Hans E Kaiser
Journal:  In Vivo       Date:  2004 Nov-Dec       Impact factor: 2.155

Review 8.  Management of and prognosis with medulloblastoma: therapy at a crossroads.

Authors:  Roger J Packer; Gilbert Vezina
Journal:  Arch Neurol       Date:  2008-11

9.  Control of apoptosis and mitotic spindle checkpoint by survivin.

Authors:  F Li; G Ambrosini; E Y Chu; J Plescia; S Tognin; P C Marchisio; D C Altieri
Journal:  Nature       Date:  1998-12-10       Impact factor: 49.962

10.  Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome.

Authors:  J R Fangusaro; Y Jiang; M P Holloway; H Caldas; V Singh; D R Boué; J Hayes; R A Altura
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

View more
  4 in total

1.  Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.

Authors:  Shruti Patil; Umesh T Sankpal; Myrna Hurtado; W Paul Bowman; Jeffrey Murray; Kathleen Borgmann; Anuja Ghorpade; Robert Sutphin; Don Eslin; Riyaz Basha
Journal:  Gene       Date:  2019-04-13       Impact factor: 3.688

Review 2.  Targeting the apoptosis pathway to treat tumours of the paediatric nervous system.

Authors:  Marie-Claire Fitzgerald; Philip J O'Halloran; Niamh M C Connolly; Brona M Murphy
Journal:  Cell Death Dis       Date:  2022-05-14       Impact factor: 9.685

3.  Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.

Authors:  Don Eslin; Chris Lee; Umesh T Sankpal; Pius Maliakal; Robert M Sutphin; Liz Abraham; Riyaz Basha
Journal:  Tumour Biol       Date:  2013-05-18

4.  Survivin expression and serum levels in pancreatic cancer.

Authors:  He Dong; Dongmeng Qian; Yaqiu Wang; Lingsheng Meng; Dong Chen; Xiangyu Ji; Wei Feng
Journal:  World J Surg Oncol       Date:  2015-05-28       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.